The United Laboratories International Holdings Limited (ULIHF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
The United Laboratories International Holdings Limited (ULIHF) trades at $1.24 with AI Score 48/100 (Grade C). The United Laboratories International Holdings Limited is a pharmaceutical company focused on the research, development, manufacture, and sale of… Market cap: $2.44B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for ULIHF: ULIHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ULIHF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ULIHF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
The United Laboratories International Holdings Limited (ULIHF) Healthcare & Pipeline Overview
The United Laboratories International Holdings Limited (ULIHF) is a global pharmaceutical company specializing in the development, manufacturing, and distribution of a wide range of pharmaceutical products, including antibiotics, anti-cold medicines, and cardiovascular drugs. Operating across multiple segments and geographies, ULIHF maintains a strong market position with a focus on both API and finished products.
What Is the Investment Thesis for ULIHF?
The United Laboratories International Holdings Limited presents a compelling investment case based on its diversified product portfolio, global reach, and integrated business model. With a P/E ratio of 7.0 and a dividend yield of 5.54%, the company offers potential value and income to investors. Its strong profit margin of 21.7% and gross margin of 47.2% indicate efficient operations and pricing power. Upcoming catalysts include potential regulatory approvals for new drugs and expansion into new geographic markets. The company's focus on both API and finished products provides a buffer against market fluctuations. However, potential risks include regulatory challenges, competition from generic drug manufacturers, and fluctuations in raw material prices. The company's low beta of 0.14 suggests relatively low volatility compared to the broader market.
Based on FMP financials and quantitative analysis
ULIHF Key Highlights
Market capitalization of $2.44B indicates a substantial presence in the pharmaceutical industry.
- P/E ratio of 7.0 suggests the company may be undervalued compared to its earnings.
- Profit margin of 21.7% demonstrates efficient operations and profitability.
- Gross margin of 47.2% reflects strong pricing power and cost management.
- Dividend yield of 5.54% provides an attractive income stream for investors.
Who Are ULIHF's Competitors?
ULIHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ANSLF Ansell Limited | $21.64 | +0.00% | $3.05B | 57 |
| DNPUF Sumitomo Pharma Co., Ltd. | $8.41 | +0.00% | $3.77B | 59 |
| HMDCF HUTCHMED (China) Limited | $2.16 | +0.00% | $1.88B | 44 |
| HYPMY Hypera S.A. | $4.05 | -0.25% | $2.85B | 45 |
| LVZPF Livzon Pharmaceutical Group Inc. | $5.22 | +0.00% | $6.06B | 49 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
| AVDL Avadel Pharmaceuticals plc | $21.64 | +0.00% | $2.12B | 64 |
| ANIP ANI Pharmaceuticals, Inc. | $77.32 | -0.90% | $1.76B | 95 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ULIHF's Key Strengths?
Diversified product portfolio.
- Global presence and distribution network.
- Integrated business model.
- Strong financial performance (profit and gross margins).
What Are ULIHF's Weaknesses?
Reliance on generic drug market, subject to price erosion.
- Exposure to regulatory risks and compliance requirements.
- Potential competition from larger pharmaceutical companies.
- Dependence on key suppliers for raw materials.
What Could Drive ULIHF Stock Higher?
Expansion into new geographic markets, particularly in emerging economies, could drive revenue growth.
- Development and launch of new pharmaceutical products targeting unmet medical needs.
- Strategic acquisitions and partnerships to expand product portfolio and market reach.
- Increased focus on API manufacturing to improve cost structure and supply chain resilience.
- Potential regulatory approvals for new drugs in key markets.
What Are the Key Risks for ULIHF?
Intense competition from generic drug manufacturers could erode pricing power and market share.
- Stringent regulatory requirements and potential delays in approvals could impact product development and commercialization.
- Fluctuations in raw material prices could affect profitability.
- Intellectual property rights infringement could lead to legal challenges and financial losses.
- Dependence on key suppliers for raw materials could disrupt supply chain.
What Are the Growth Opportunities for ULIHF?
- Expansion into Emerging Markets: ULIHF can capitalize on the growing demand for affordable medicines in emerging markets such as Southeast Asia and Africa. These regions are experiencing rapid economic growth and increasing healthcare expenditure, creating significant opportunities for pharmaceutical companies. By establishing a stronger presence in these markets, ULIHF can diversify its revenue streams and reduce its reliance on developed countries. Timeline: Ongoing.
- Development of New Pharmaceutical Products: Investing in research and development to create innovative pharmaceutical products can drive long-term growth for ULIHF. Focusing on therapeutic areas with unmet needs, such as diabetes and cardiovascular diseases, can lead to the development of blockbuster drugs. The global market for diabetes drugs is projected to reach $60 billion by 2028. Timeline: Ongoing.
- Strategic Acquisitions and Partnerships: ULIHF can pursue strategic acquisitions and partnerships to expand its product portfolio and geographic reach. Acquiring smaller pharmaceutical companies with complementary products or technologies can accelerate growth and enhance competitiveness. Collaborating with research institutions and universities can also facilitate the development of new drugs. Timeline: Ongoing.
- Increased Focus on API Manufacturing: Strengthening its API (Active Pharmaceutical Ingredient) manufacturing capabilities can enhance ULIHF's vertical integration and reduce its reliance on external suppliers. The global API market is estimated to reach $250 billion by 2027. By producing its own APIs, ULIHF can improve its cost structure and ensure a stable supply of raw materials. Timeline: Ongoing.
- Leveraging Technological Advancements: Adopting advanced technologies such as artificial intelligence and machine learning can improve ULIHF's drug discovery and development processes. These technologies can accelerate the identification of potential drug candidates, optimize clinical trial design, and enhance manufacturing efficiency. Investing in digital health solutions can also create new revenue streams. Timeline: Ongoing.
What Are ULIHF's Competitive Advantages?
- Diversified product portfolio across multiple therapeutic areas.
- Global presence with operations in various countries.
- Integrated business model encompassing research, development, manufacturing, and distribution.
- Established brand reputation and customer relationships.
What Does ULIHF Do?
Founded in 1990 and headquartered in Yuen Long, Hong Kong, The United Laboratories International Holdings Limited has evolved into a significant player in the pharmaceutical industry. The company operates as an investment holding entity with a primary focus on the research, development, manufacture, distribution, and sale of pharmaceutical products. Its operations are structured into three key segments: Bulk Medicine, Intermediate Products, and Finished Products. These segments allow the company to cater to different stages of the pharmaceutical value chain, from raw materials to end-user products. ULIHF's product portfolio is diverse, encompassing oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules. Additionally, the company manufactures and sells soft capsule casings and trades in pharmaceutical products. The company's geographic reach extends across the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally, demonstrating its global presence and market penetration. The company also provides management services. With a workforce of 17,000 employees, ULIHF has established a robust infrastructure to support its extensive operations. This includes research and development facilities, manufacturing plants, and distribution networks that enable the company to efficiently deliver its products to various markets. The company's commitment to research and development is evident in its continuous efforts to innovate and expand its product offerings, addressing the evolving needs of the healthcare industry.
What Products and Services Does ULIHF Offer?
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical products, including oral antibiotics and injectables.
- Distributes pharmaceutical products to various markets.
- Sells pharmaceutical products through multiple channels.
- Produces bulk medicine and intermediate products.
- Offers finished pharmaceutical products for various therapeutic areas.
- Manufactures and sells soft capsule casings.
- Trades in pharmaceutical products.
How Does ULIHF Make Money?
- Develops and manufactures a wide range of generic pharmaceutical products.
- Sells products through three segments: Bulk Medicine, Intermediate Products, and Finished Products.
- Generates revenue through the sale of pharmaceutical products in various markets, including China, Europe, and Asia.
What Industry Does ULIHF Operate In?
The United Laboratories International Holdings Limited operates in the global pharmaceutical industry, which is characterized by intense competition, stringent regulations, and continuous innovation. The market for generic drugs is expanding, driven by cost containment measures and patent expirations. ULIHF competes with other generic drug manufacturers, as well as larger pharmaceutical companies with branded products. Key trends include the increasing demand for affordable medicines, the growing prevalence of chronic diseases, and the rising healthcare expenditure in emerging markets. Competitors include ANSLF (Amneal Pharmaceuticals), DNPUF (Dr. Reddy's Laboratories), HMDCF (Hikma Pharmaceuticals), HYPMY (Hypharm Inc), and LVZPF (Lupin Limited).
Who Are ULIHF's Key Customers?
- Hospitals and clinics.
- Pharmacies and drug stores.
- Wholesalers and distributors.
- Patients and consumers.
Forward Outlook
Wall Street analysts project The United Laboratories International Holdings Limited revenue of about $12.36B for fiscal 2026, with EPS near $0.52. The estimate reflects 9 contributing analysts.
Earnings Track Record
The United Laboratories International Holdings Limited has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 21.0% above estimates on average.
Financial Health
The United Laboratories International Holdings Limited's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.91 places it in the grey zone, a middle ground that warrants monitoring.
Key Financial Metrics
Return on equity for The United Laboratories International Holdings Limited stands at 12.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 6.7%, showing how much profit it generates from its asset base. ULIHF trades at a trailing price-to-earnings ratio of 6.97, below the Healthcare sector average of ~23x. Its free cash flow yield is 6.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.83 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 14.3%, the inverse of the P/E and a quick read on earnings relative to price.
The United Laboratories International Holdings Limited (ULIHF) Valuation Context
Valued at $2.44B, ULIHF is classified as a mid-cap stock. Relative to its peer group, ULIHF's quantitative score of 48/100 is roughly in line with the peer average of 51/100.
ULIHF Revenue & Earnings Trend
In Q4 2025, ULIHF generated $5.60B in top-line revenue, marking a sequential decrease of 25.6%. The company recorded net income of $188.4M, with diluted EPS of $0.06. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ULIHF averaged $0.64 in diluted EPS.
Company Profile
The United Laboratories International Holdings Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Yuen Long, HK. The company is led by CEO Hoi Shan Tsoi. ULIHF has traded publicly since 2014.
ULIHF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future growth potential, indicating a positive outlook from leadership.
- Community sentiment has shifted positively as discussions around ULIHF's innovative product lines gain traction among investors.
- Market perception has improved due to recent strategic partnerships that may enhance distribution and market reach.
- The company has shown resilience in navigating supply chain challenges, which has bolstered investor trust in its operational capabilities.
Bear Case
- Some analysts express concerns about the competitive landscape, highlighting potential challenges from emerging market players.
- Recent social sentiment indicates skepticism regarding the sustainability of ULIHF's recent growth, with some investors questioning long-term viability.
- There are apprehensions about regulatory changes that could impact operations, leading to uncertainty among market participants.
- Negative discussions around the company's financial transparency have surfaced, causing some investors to reconsider their positions.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $5.60B | $188M | $0.06 |
| Q2 2025 | $7.52B | $1.89B | $1.04 |
| Q4 2024 | $6.58B | $1.17B | $0.64 |
| Q2 2024 | $7.18B | $1.49B | $0.82 |
Based on FMP financials and quantitative analysis
ULIHF Latest News
No recent news available for ULIHF.
ULIHF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ULIHF.
Price Targets
Wall Street price target analysis for ULIHF.
ULIHF MoonshotScore
What does this score mean?
The MoonshotScore rates ULIHF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Hoi Shan Tsoi
CEO
Hoi Shan Tsoi serves as the CEO of The United Laboratories International Holdings Limited, overseeing the strategic direction and operational management of the company's extensive pharmaceutical operations. With a career dedicated to the healthcare sector, Tsoi brings a wealth of experience in pharmaceutical manufacturing, distribution, and market expansion. His leadership is instrumental in guiding the company's growth trajectory and maintaining its competitive edge in the global pharmaceutical landscape. Tsoi is responsible for managing a workforce of 17,000 employees.
Track Record: Under Hoi Shan Tsoi's leadership, The United Laboratories International Holdings Limited has expanded its global footprint and diversified its product portfolio. Key achievements include the successful launch of new pharmaceutical products, strategic partnerships with international distributors, and improved operational efficiencies. Tsoi's strategic decisions have contributed to the company's strong financial performance and enhanced its reputation as a reliable supplier of quality pharmaceutical products.
ULIHF OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) securities. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure and may not meet minimum listing requirements. This tier typically includes companies with limited operating history, distressed companies, or those that choose not to comply with the stricter reporting standards of higher-tier exchanges. Investing in OTC Other stocks carries significant risk due to the lack of transparency and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in ULIHF.
- Low trading volume and liquidity can lead to price volatility.
- Potential for fraud or manipulation due to the lack of regulatory oversight.
- Higher bid-ask spreads can increase trading costs.
- OTC Other tier stocks may be subject to delisting or suspension.
- Verify the company's registration and legal status.
- Assess the company's financial condition and operating performance.
- Review the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Monitor the company's news and announcements for any material developments.
- The United Laboratories International Holdings Limited has been in operation since 1990.
- The company has a global presence with operations in multiple countries.
- The company has a diversified product portfolio across various therapeutic areas.
- The company has a substantial market capitalization of $2.44B.
- The company has a dividend yield of 5.54%.
Common Questions About ULIHF (Healthcare)
What does the AI Score mean for ULIHF?
ULIHF holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. The United Laboratories International Holdings Limited is a pharmaceutical company focused on the research, development, manufacture, and sale of pharmaceutical products across various therapeutic …
What does The United Laboratories International Holdings Limited do?
The United Laboratories International Holdings Limited is a pharmaceutical company that researches, develops, manufactures, and sells a wide range of pharmaceutical products. These products include oral antibiotics, antimicrobials for injection, anti-cold products, and drugs for treating conditions like diabetes, hepatitis B, and cardiovascular diseases.
What are the main risks for ULIHF?
ULIHF faces several risks inherent to the pharmaceutical industry. Intense competition from generic drug manufacturers can put pressure on pricing and market share. Stringent regulatory requirements and potential delays in drug approvals can impact the company's ability to bring new products to market. Fluctuations in raw material prices can affect profitability.
What are the key factors to evaluate for ULIHF?
The United Laboratories International Holdings Limited (ULIHF) holds an AI score of 48/100 (low). P/E: 7.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does ULIHF data refresh on this page?
ULIHF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ULIHF's recent stock price performance?
The United Laboratories International Holdings Limited (ULIHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ULIHF overvalued or undervalued right now?
The United Laboratories International Holdings Limited (ULIHF) trades at 7.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ULIHF before investing?
Before investing in The United Laboratories International Holdings Limited (ULIHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ULIHF to a portfolio?
Key strength of The United Laboratories International Holdings Limited (ULIHF): Diversified product portfolio. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis is pending, which may provide further insights into the company's prospects.
- OTC market stocks carry higher risks due to limited disclosure and liquidity.